产品
编 号：F511564
分子式：C19H15ClN2O4
分子量：370.79
分子式：C19H15ClN2O4
分子量：370.79
产品类型
规格
价格
是否有货
10mM*1mL in DMSO
询价
询价
500mg
320
In-stock
1g
400
In-stock
5g
1296
In-stock
结构图
CAS No: 90098-04-7
产品详情
生物活性：
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer.
体内研究：
Rebamipide (5，15，50 mg/kg；口服 每天一次，连续14天) 增强大鼠胃粘膜COX-2和PGE2的表达，保护胃粘膜免受酸损伤。Animal Model:Specific pathogen-free male Sprague-Dawley rats (200-230 g; 7-week-old).
Dosage:5, 15, 50 mg/kg
Administration:Oral administration; once daily for 14 days.
Result:Increased the level of COX-2 immunoreactivity and PGE2 in a dose-dependent manner. (PGE2 is implicated in protection of gastric mucosa from various insults and acceleration of gastric wound healing).Inhibited intragastric HCl administration-induced gastric mucosal bleeding and erosion.
体外研究：
Rebamipide (1.4，2.7，5.4 mM；24 h) 抑制胃癌细胞增殖。 Rebamipide (5.4 mM；30 min) 激活 AGS 细胞中的 Smad 信号通路。 Rebamipide (5.4 mM；3 h) 在AGS细胞中诱导Cdk抑制剂p21的表达。
Rebamipide (OPC12759) is an orally active gastroprotective agent that enhances the production of endogenous PGs (especially intragastric PGE2) by inducing COX-2 expression, thereby protecting the gastric mucosa from injury. Rebamipide exerts anti-proliferative activity against gastric cancer cells. Rebamipide can be used in studies of mucosal protection, gastroduodenal ulcer, gastritis and gastric cancer.
体内研究：
Rebamipide (5，15，50 mg/kg；口服 每天一次，连续14天) 增强大鼠胃粘膜COX-2和PGE2的表达，保护胃粘膜免受酸损伤。Animal Model:Specific pathogen-free male Sprague-Dawley rats (200-230 g; 7-week-old).
Dosage:5, 15, 50 mg/kg
Administration:Oral administration; once daily for 14 days.
Result:Increased the level of COX-2 immunoreactivity and PGE2 in a dose-dependent manner. (PGE2 is implicated in protection of gastric mucosa from various insults and acceleration of gastric wound healing).Inhibited intragastric HCl administration-induced gastric mucosal bleeding and erosion.
体外研究：
Rebamipide (1.4，2.7，5.4 mM；24 h) 抑制胃癌细胞增殖。 Rebamipide (5.4 mM；30 min) 激活 AGS 细胞中的 Smad 信号通路。 Rebamipide (5.4 mM；3 h) 在AGS细胞中诱导Cdk抑制剂p21的表达。
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备